ICER

ICER weighing issuing advice on trial design
ICER weighing issuing advice on trial design
BioCentury
ICER
clinical trials
trial design
Flag link:
Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says
Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says
Biopharma Dive
insurers
ICER
migraines
CGRP
coverage limits
Flag link:
Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail
Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail
Fierce Pharma
Amgen
ICER
Aimovig
migraines
Flag link:
AbbVie's elagolix could put pressure on budgets, ICER estimates
AbbVie's elagolix could put pressure on budgets, ICER estimates
Biopharma Dive
AbbVie
endometriosis
ICER
Elagolix
Flag link:
Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing
Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing
Fierce Pharma
Roche
Hemlibra
hemophilia
FDA
breakthrough status
ICER
Flag link:
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
CAR-T
ICER
Gilead Sciences
Yescarta
Novartis
Kymriah
drug pricing
Flag link:
Vantage view – Payers OK with CAR-T? Not so fast
Vantage view – Payers OK with CAR-T? Not so fast
EP Vantage
CAR-T
payers
ICER
Flag link:
Should pharma fear ICER?
Should pharma fear ICER?
Medical Marketing and Media
ICER
Flag link:
New anti-PD1 drugs overpriced, ICER says
New anti-PD1 drugs overpriced, ICER says
BioPharma Dive
drug pricing
ICER
anti-PD-L1
Opdivo
Keytruda
Bristol-Myers Squibb
Merck
Flag link:
Nonprofit seeks to dispel ‘myths’ about how it assesses drug values
Nonprofit seeks to dispel ‘myths’ about how it assesses drug values
Stat
drug pricing
ICER
Flag link: